Your browser doesn't support javascript.
loading
Biomarkers in dementia: clinical utility and new directions.
Ahmed, R M; Paterson, R W; Warren, J D; Zetterberg, H; O'Brien, J T; Fox, N C; Halliday, G M; Schott, J M.
Afiliação
  • Ahmed RM; Neuroscience Research Australia and the University of NSW, Sydney, New South Wales, Australia.
  • Paterson RW; Dementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
  • Warren JD; Dementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
  • Zetterberg H; Department of Molecular Neuroscience, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Institute of Neuroscience and Physiology, Mölndal
  • O'Brien JT; Department of Psychiatry, University of Cambridge, Cambridge, UK.
  • Fox NC; Dementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
  • Halliday GM; Neuroscience Research Australia and the University of NSW, Sydney, New South Wales, Australia.
  • Schott JM; Dementia Research Centre, University College London Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
J Neurol Neurosurg Psychiatry ; 85(12): 1426-34, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25261571
ABSTRACT
Imaging, cerebrospinal fluid (CSF) and blood-based biomarkers have the potential to improve the accuracy by which specific causes of dementia can be diagnosed in vivo, provide insights into the underlying pathophysiology, and may be used as inclusion criteria and outcome measures for clinical trials. While a number of imaging and CSF biomarkers are currently used for each of these purposes, this is an evolving field, with numerous potential biomarkers in varying stages of research and development. We review the currently available biomarkers for the three most common forms of neurodegenerative dementia, and give an overview of research techniques that may in due course make their way into the clinic.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Demência Limite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Demência Limite: Humans Idioma: En Revista: J Neurol Neurosurg Psychiatry Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Austrália